This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Iteos Belgium Sa. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Michael Deligny: Inventor in Cancer Therapeutics
Introduction
Michael Deligny is an inventor based in Rhode-Saint-Genese, Belgium. His patent work concerns potential cancer treatments involving macrocyclic diamine derivatives and adenosine receptor antagonists.
Latest Patents
Deligny is associated with 1 patent: “Macrocyclic Diamine Derivatives as ENT Inhibitors for the Treatment of Cancers, and Combination Thereof with Adenosine Receptor Antagonists.” The invention describes macrocyclic diamine derivatives, including their pharmaceutically acceptable salts and solvates, as inhibitors of equilibrative nucleoside transporter (ENT) family proteins, particularly ENT1. It presents these compounds as potential therapeutic agents for cancer and also describes their combined use with an adenosine receptor antagonist.
Career Highlights
Deligny is associated with Iteos Belgium SA. His patent reflects research into targeting ENT transporters and combining that approach with adenosine receptor antagonism for cancer treatment.
Collaborations
His listed coworker is Stefano Crosignani. Their association is connected to the patent concerning ENT inhibitors and potential cancer therapies.
Conclusion
Michael Deligny’s patent work focuses on a proposed combination-based approach to cancer treatment, using macrocyclic diamine derivatives to inhibit ENT transporters alongside adenosine receptor antagonists.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile